US FDA Inspection at Piramal Pharma's facility located at Turbhe

The US FDA conducted General GMP inspection at Piramal Pharma Limited's Turbhe facility from 11th February, 2025 to 17th February, 2025.

On conclusion of the inspection, a Form-483 was issued with 6 observations. Observations are largely around improvement of procedures and practices and not related to data integrity. The Company is preparing a detailed response to said observations, which will be submitted to agency within stipulated timelines.

The Company remains committed to maintain a highest standards of compliance and is confident of effective closure of observations.

Shares of Piramal Pharma Limited was last trading in BSE at Rs. 197.65 as compared to the previous close of Rs. 199.85. The total number of shares traded during the day was 394264 in over 5152 trades.

The stock hit an intraday high of Rs. 205.30 and intraday low of 192.80. The net turnover during the day was Rs. 78072065.00.

Source : Equity Bulls

Keywords

PiramalPharma PPLPHARMA INE0DK501011 Pharmaceuticals USFDA Inspection Turbhe Form483 6Observations